| Autor: |
Arasu, Alexis, Lee, Senhong, Chian Yeoh, Aun, Ross, Gayle |
| Předmět: |
|
| Zdroj: |
Australasian Journal of Dermatology; Feb2021, Vol. 62 Issue 1, pe107-e109, 3p, 3 Charts, 1 Graph |
| Abstrakt: |
Dear Editor, Thalidomide is an immunomodulatory drug which has demonstrated success across several refractory dermatological conditions.1-3 Its mechanism remains poorly understood and is uncommonly prescribed in the field of dermatology, usually as a last-line therapeutic option.4 Historically, there has been hesitation limiting its use, attributed to its significant adverse effect profile.5 Drug survival is a useful indicator of the viability of a drug taking into account effectiveness, tolerability and safety. We present an experience of using thalidomide in 28 patients with a range of dermatoses recalcitrant to conventional treatments. Of the 28 patients in our study, 25 ceased the drug within 2 years of commencement due to adverse effects or lack of effectiveness, both influencing drug survival. Three of the patients currently remain on the drug, with one patient remaining on therapy for 38 years experiencing minimal side effects and complete response during treatment. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
